

VU Research Portal

Design and Synthesis of New Histamine H4 Receptor Ligands

Smits, R.A.

2009

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Smits, R. A. (2009). *Design and Synthesis of New Histamine H4 Receptor Ligands*. [PhD-Thesis - Research and graduation internal, Vrije Universiteit Amsterdam].

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

CHAPTER 5**Synthesis and QSAR of quinazoline sulfonamides as highly potent human histamine H₄ receptor inverse agonists.**

Smits, R., A.^a; Istyastono, E., Adami, M.^b; P.^a Zuiderveld, O., P.^a van Dam, C., M., E.^a de Kanter, F.^a Jongejan, A.^a Coruzzi, G.^b Leurs, R.^a de Esch, I., J., P.^a

^aLeiden/Amsterdam Center for Drug Research (LACDR), Division of Medicinal Chemistry, Department of Pharmacochemistry, Faculty of Exact Sciences, Vrije Universiteit Amsterdam, De Boelelaan 1083, 1081 HV Amsterdam, The Netherlands.

^bDepartment of Human Anatomy, Pharmacology and Forensic Medicine, Section of Pharmacology, University of Parma, via Volturno 39, 43100 Parma, Italy.

Manuscript Submitted

Abstract

Hit optimization of the class of quinazoline containing histamine H₄ receptor (H₄R) ligands resulted in a sulfonamide substituted analogue with high affinity for the H₄R. This moiety leads to improved physicochemical properties and is believed to probe a distinct H₄R binding pocket that was previously identified using pharmacophore modeling. By introducing a variety of sulfonamide substituents, the H₄R affinity was optimized. The interaction of the new ligands, in combination with a set of previously published quinazoline compounds was described by a QSAR equation. Pharmacological studies revealed that the sulfonamide analogues have excellent H₄R affinity and behave as inverse agonists at the human H₄R. *In vivo* evaluation of the potent 2-(6-chloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-N-phenylethanesulfonamide (**54**) (pK_i= 8.31±.10), revealed it to have anti-inflammatory activity in an animal model of acute inflammation.

Introduction

The histamine H₄R receptor (H₄R) is a G-protein coupled receptor (GPCR) that belongs to the histamine receptor family which is comprised of the H₁R, H₂R, H₃R and H₄R receptors.¹ After its discovery in 2000, the H₄R has attracted much attention because it plays a role as a mediator of allergic and inflammatory processes.^{2,3} This receptor is mostly found in peripheral tissues but its RNA (ribonucleic acid) has also been found in the brain.⁴ The H₄R is expressed on cells of the immune system and blood forming organs.^{5,6,7} A considerable amount of work has been done to clarify the role of the H₄R in (patho)physiological processes and H₄R ligands have been shown to be efficacious in a variety of animal models of inflammatory disease.^{3,8,9} Although the H₄R is considered a potential drug target for the treatment of asthma, allergic rhinitis (hay fever) and pruritis (itch), it has not yet been validated for these clinical applications. Most compounds that have been used for the elucidation of the role of the H₄R have unfavorable kinetics such as low half-life (JNJ777120) or lack of selectivity (thioperamide, clobenpropit).^{10,11} To firmly establish the clinical potential of H₄R ligands, there remains a need for good pharmacological tools that do not suffer from the abovementioned problems.

Recently we described a pharmacophore model for the H₄R that was subsequently used in a rational fragment based drug discovery approach for the development of potent quinoxaline H₄R ligands.¹² Subsequent scaffold hopping from the quinoxaline to the quinazoline heterocycle led to the identification of thiophene and furan substituted quinazolines **1** and **2** (Figure 1).¹³ Although the H₄R affinity of quinazolines **1** and **2** is high, an effort was made to replace the thiophene (VUF10497) and furan (VUF10499) moieties.¹³ Both these compounds are quite lipophilic and the introduction of polar replacements for the thiophene and furan moieties was considered to be beneficial for solubility. Therefore, several amines were coupled to the quinazoline scaffold leading to the identification of a sulfonamide substituted quinazoline with high affinity for the H₄R (compound **3**, Figure 1). The identification of compound **3** was followed-up with a SAR study in order to explore the tolerance to substitution and alteration of the newly discovered *N*-ethyl sulfonamide group. Several analogues were synthesized and evaluated for H₄R affinity to study the effects of various substituents on the sulfonamide nitrogen, chain length or the replacement of the sulfonamide moiety with several bioisosteres.





Figure 1: H_4R Inverse agonists **1** and **2** and newly discovered sulfonamide substituted quinazoline **3** with high affinity for the histamine H_4 receptor.

Substituents on the 4-position of both the initial series of quinazoline compounds and the new sulfonamide-containing quinazolines are believed to occupy the same pocket in the H_4R binding site. This unique pocket was discovered after the construction of a pharmacophore model, based on reference H_4R antagonist JNJ7777120 and H_4R agonist clozapine.^{12,13,14} In an effort to more quantitatively describe the binding of the compounds in the H_4R pocket a QSAR model was constructed, using the H_4R affinity data of a significant number of previously reported quinazoline compounds¹³, in combination with the new sulfonamide compounds described in this publication.


Chemistry

The quinazoline sulfonamides were synthesized by a converging synthesis route that requires the preparation of both the sulfonamide- and 2,4-dichloroquinazoline precursors that can subsequently be coupled together. Treatment of the combined intermediate quinazoline with *N*-methylpiperazine then gives the desired compounds. Starting from taurine (**4a**), sulfonic acid **5a** was synthesized according to a procedure described in literature (Scheme 1).¹⁵ Subsequent treatment of **5a** with PCl_5 then gave sulfonylchloride **6a**.¹⁵ The same synthetic sequence was used for the preparation of **6b** from its precursors **4b** and **5b**. The conversion of **6** to various sulfonamide analogues **7a**, **7b** and **8-12** was carried out successfully in a number of solvents such as dioxane and chloroform with an excess of the corresponding amines. Deprotection of the terminal amine functionality of the sulfonamide precursors gave primary amines **13a**, **13b** and **14-18**. Efficient deprotection was achieved using hydrazine in ethanol, following a procedure described in literature for the synthesis of 2-aminoethanesulfonamide hydrochloride (**10**).¹⁶

Scheme 1^a


^a Reagents and conditions: a) phthalic anhydride, KOAc, AcOH; b) PCl_3 , toluene; c) R_1NR_2 , r.t.; d) H_2NNH_2 , EtOH.

β -Alanine (**19**) was reacted with phthalic anhydride in the presence of potassium acetate and acetic acid (scheme 2). The intermediate salt (**20**) was converted to its corresponding acid chloride (**21**) with thionylchloride. This freshly prepared acid chloride was used immediately to react with *N*-methylaniline to form carboxamide **22**. The nitrogen in the phthalimide group in this carboxamide was deprotected with hydrazine in ethanol to give primary amine **23**.

Scheme 2^a

^a Reagents and conditions: a) AcOH, KOAc, reflux; b) SOCl_2 , DMF, DCM, reflux; c) *N*-methylaniline, DCM, r.t.; d) H_2NNH_2 , EtOH, reflux.

Anthranilic acids **24-31** with various aromatic substituents were treated with molten urea to give quinazoline-2,4(1*H*,3*H*)-diones **32-39** in excellent yields (scheme 3).¹⁷ As has been described earlier for 2,4,6-trichloroquinazoline, these intermediates were then chlorinated with phosphorous oxychloride in the presence of diisopropyl ethylamine to give key 2,4-dichloroquinazoline intermediates **40-47**.¹³

Scheme 3^a

^a Reagents and conditions: a) urea, 160°C; b) 0.5 M NaOH; c) *N,N*-diethylaniline, POCl₃, reflux; d) NH₂R, DIPEA, EtOAc, r.t.; e) *N*-methylpiperazine, microwave, 120°C, 10 min.

















Primary amines **13a**, **13b**, **14-18** and several commercially available primary amines were then coupled selectively to the 4-position of the different 2,4-dichloroquinazolines at room temperature in the presence of diisopropylethylamine (DIPEA). Conversions were typically very high and upon completion excess *N*-methylpiperazine was added and coupled to the 2-position using microwave assisted heating. Using this previously described one-pot procedure, no work-up of the 4-substituted quinazoline intermediate was required and target compounds **3**, **48-61**, **82** and **98-104** were obtained in good to excellent yields.¹² The experimental procedures for the synthesis of these compounds and their corresponding intermediates are described in the experimental section and supporting information of this manuscript. Experimental details for the synthesis of the previously synthesized compounds used in the QSAR model are described in literature.¹³

Results and discussion

In an attempt to improve the solubility of **1** and **2** (Figure 1) we replaced the aromatic heterocycles of these compounds by a variety of more polar moieties. Using parallel synthesis, our library of primary amines was coupled to intermediate **40** to give a series of quinazoline-containing compounds, including diethyl sulfonamide **3**. H₄R affinity screening of this compound revealed high affinity ($pK_i = 8.12$), and it was therefore chosen as a starting point for further optimization and exploration of the SAR of this compound.

When the diethyl sulfonamide of **3** is replaced with a dimethylsulfonamide (**48**, Table 1) a comparable affinity is found. Removal of one of the methyl groups from **48** leads to a 3-fold increase in potency (compare **48** and **49**). When the diethyl groups of **3** are constrained in a cyclic pyrrolidine system (compound **50**) some affinity is lost, although some other fused rings are well tolerated as illustrated by 2-methylpiperidine and morpholine analogues **51** and **52**. The replacement of one of the methyl substituents of **48** with a phenyl group, leading to compound **53** increases the affinity slightly but no further increase was observed when the *N*-methyl group was removed (compare **53** and **54**). Substitution of the sulfonamide phenyl ring of **54** with a 4-iodo substituent gives a 14-fold decrease in H₄R affinity (**55**). Although the exact reason of this decrease is unknown it can be speculated that the 4-iodophenyl group is simply too large to be accommodated by the H₄R. When the ethylene spacer between the nitrogen atom on the 4-position of the quinazoline and the sulfonamide group was extended, a drop in affinity was observed (compare **49** and **56**), which suggests an optimal spacer length of two methylene units between the sulfonamide moiety and the quinazoline heterocycle. Replacement of the –NH₂ group of the sulfonamide moiety with a methyl group gave sulfone **57** that has decreased H₄R affinity compared to most sulfonamides in Table 1 and indicates the importance of the basic nitrogen group for H₄R binding. In fact, when the sulfonamide moiety remains unsubstituted as in compound **58**, the highest affinity ($pK_i = 8.35$) is observed. The importance of the sulfonamide group for H₄R binding is emphasized by the failure to replace the sulfonamide group with a suitable bioisostere. Indeed, carboxamide (compound **59**), reversed carboxamide (compound **60**) or thiazolidinedione (compound **61**) all failed to give compounds with good H₄R affinity.

Table 1: SAR study of the sulphonamide side chain of quinazoline H₄R ligands.

					
No	R ₂	pK _i ±SEM ^a	No	R ₂	pK _i ±SEM ^a
3		8.12 ± 0.05	55		7.15 ± 0.18
48		7.90 ± 0.09	56		7.48 ± 0.29
49		8.37 ± 0.17	57		7.57 ± 0.18
50		7.75 ± 0.13	58		8.35 ± 0.08
51		8.00 ± 0.11	59		6.65±0.11
52		8.03 ± 0.16	60		6.31±0.09
53		8.27± 0.01	61		6.75±0.11
54		8.31 ± 0.10			





^a Measured by displacement of [³H]histamine binding using membranes of HEK cells transiently expressing the human H₄R. pK_i's are calculated from at least three independent measurements as the mean ± SD.


























This SAR study demonstrates that substitution of the quinazoline heterocycle with various *N*-ethylaminosulfonamides leads to highly potent H₄R ligands. Most importantly, the amino group in the sulfonamide moiety of these quinazolines is quite tolerant to substitution with a variety of aromatic and aliphatic groups leading to many compounds with affinities in the single-digit nanomolar range.











In parallel with the preparation of several new sulfonamide analogues a QSAR study was performed on a large number of quinazolines that was previously prepared during our H₄R drug discovery program.¹³ The H₄R affinities (pK_i values) of all compounds used in the QSAR study have all been generated in the same H₄R radioligand displacement assay.¹³ A

total of 44 compounds were selected and divided into two sets, 31 compounds were put in the training set and 13 compounds were put in the test set (Table 2). All computational chemistry work was performed on an AMD Athlon™ 3500+ 2.2GHz, with 2 GB RAM using Molecular Operating Environment (MOE, version 2006.08, Chemical Computing Group Inc, Canada).¹⁸ All structures were drawn with the builder module of MOE. Conformational analysis using the stochastic conformation search algorithm was then performed using the conformational import module provided by MOE with no filters and no constraints applied. The conformational analysis and energy minimization were performed using stochastic conformation search with a RMS gradient of 0.001 Å and iteration limit of 10,000 using the MMFF94 force field.¹⁹⁻²¹ All non-quantum chemical descriptors provided within the MOE software were then calculated for the lowest energy conformations. The relationship between the H₄R pK_i and the descriptors of the training set was identified by stepwise regression analysis using SPSS 14.0 for Windows. The following statistical measures were used: *N* = number of samples, *F*-test for quality of fit, *r* = coefficient of correlation, *R*² = coefficient of determination and *S* = standard error of estimation. Equation 1 resulting from the stepwise regression analysis is considered the ‘best’ QSAR model of quinazoline derivatives as ligands of the hH₄R. The descriptors selected by stepwise regression analysis are shown in Table 3 and were found to be non-dependent on each other (the cross correlation between descriptors was < 0.7 as determined by the Pearson correlation method). In case the selected descriptors for the “best model” were not independent, the relationship was re-examined without the descriptor that had the lowest correlation with the affinity. The observed, calculated and predicted (leave-one-out) affinity values of the training set are presented in Table 4.

Table 2. H₄R affinity of quinazoline derivatives used as the training and test set.

							
No	R ₁	R ₂	pK _i ±SEM ^a	No	R ₁	R ₂	pK _i ±SEM ^a
Training set				78	6-Cl		7.45±0.02
1	6-Cl		8.12±0.02	79	6-Cl		6.98±0.02

3	6-Cl		8.12±0.02	80	6-Cl		6.97±0.10
54	6-Cl		8.31±0.10	81	6-Cl		6.25±0.04
59	6-Cl		6.65±0.11	82	6-Cl		7.30±0.03
60	6-Cl		6.31±0.09	83	6-Cl		6.25±0.03
61	6-Cl		6.75±0.11	84	6-Cl		6.98±0.02
62	H	H	5.12±0.06	85	6-Cl		6.73±0.09
63	H		5.55±0.03	86	6-Cl		6.23±0.03
64	H	NH ₂	5.76±0.05	Test set			
65	H		5.97±0.07	2	6-Cl		7.05±0.04
66	H		5.83±0.11	53	6-Cl		8.27±0.01
67	6-Cl		6.59±0.03	87	H		5.39±0.03
68	6-Cl	NH-CH ₃	7.10±0.01	88	H		5.07±0.05
69	6-Cl		6.21±0.02	89	6-Cl		6.12±0.01 ^b
70	7-Cl	NH-CH ₃	6.02±0.03 ^b	90	6-Cl	NH ₂	6.81±0.07
71	5-CH ₃	NH-CH ₃	6.20±0.06 ^b	91	6-Cl		6.36±0.07 ^b
72	6-Cl, 8-CH ₃		6.73±0.02	92	6-Cl		6.05±0.06 ^b

73	6-F		6.65±0.03	93	H		6.22±0.01 ^b
74	6-Cl		6.87±0.02	94	6-Cl		7.47±0.04
75	6-Cl		7.57±0.05	95	6-Cl		7.41±0.04
76	6-Cl		6.43±0.01	96	6-Cl		6.44±0.01
77	6-Cl		7.22±0.03	97	6-Cl		6.89±0.13

^a Measured by displacement of [³H]histamine binding using membranes of HEK cells transiently expressing the human H₄R. pK_i's are calculated from at least three independent measurements as the mean ± SEM. ^c n=2.

Table 3: Definition of the molecular descriptors found for the H₄R QSAR model, generated with the QuaSAR Descriptor module in MOE 2006.08.

Descriptor	Definition
a_ICM	The entropy of the element distribution in the molecule
PEOE_VSA+5	Sum of the van der Waals surface area of atoms, whose PEOE ^a partial charge is between 0.25 and 0.30
PEOE_VSA-3	Sum of the van der Waals surface area of atoms, whose PEOE partial charge is between -0.20 and -0.15
PEOE_VSA_FPOS	Sum of the van der Waals surface area of atoms, whose PEOE partial charge is positive, divided by the total surface area
SMR_VSA1	The subdivided surface area descriptor based on the sum of the approximate accessible van der Waal's surface area, calculated for each atom with contribution to molar refractivity in the range of 0.11 to 0.26
GCUT_PEOE_1	A descriptor calculated from the eigenvalues of a modified graph adjacency matrix. The diagonal of the matrix takes the value of the PEOE partial charges.

^a PEOE is a partial charge descriptor calculated using the partial equalization of orbital electronegativities.

Table 4: The observed, calculated and predicted affinity values of the training and test set.

No	observed pK _i ^a	calculated pK _i ^b	predicted pK _i ^c	No	observed pK _i ^a	calculated pK _i ^b	predicted pK _i ^c
Training set				78	7.45	7.26	7.24
1	8.12	7.41	7.35	79	6.98	7.24	7.29
3	8.12	8.19	8.22	80	6.97	7.17	7.21
54	8.31	8.21	8.18	81	6.25	7.11	7.25
59	6.65	6.72	6.73	82	7.30	6.98	6.92
60	6.31	6.41	6.43	83	6.25	6.62	6.65
61	6.75	6.77	6.86	84	6.98	6.67	6.62
62	5.12	5.28	5.36	85	6.73	6.68	6.65
63	5.55	5.72	5.76	86	6.23	6.24	6.25
64	5.76	5.61	5.54	Test set			
65	5.97	5.77	5.71	2	7.05	7.02	-
66	5.83	5.67	5.60	53	8.27	8.01	-
67	6.59	6.60	6.61	87	5.39	5.94	-
68	7.10	6.85	6.83	88	5.07	5.03	-
69	6.21	6.19	6.19	89	6.12	6.59	-
70	6.02	6.73	6.79	90	6.81	6.62	-
71	6.20	5.96	5.87	91	6.36	6.54	-
72	6.73	6.90	6.93	92	6.05	6.70	-
73	6.65	6.43	6.34	93	6.22	6.16	-
74	6.87	6.86	6.86	94	7.47	7.26	-
75	7.57	7.30	7.25	95	7.41	7.45	-
76	6.43	6.42	6.41	96	6.44	6.57	-
77	7.22	7.20	7.20	97	6.89	7.32	-

^a pK_i values taken from table 2. ^b Calculated from equation 1. ^c Determined by leave-one-out method.

Equation 1.

$$\begin{aligned}
 pK_i \text{ hH}_4\text{R} = & 3.632(\pm 2.253) + 5.891(\pm 0.656) [\text{a_ICM}] \\
 & - 0.054(\pm 0.012) [\text{PEOE_VSA+5}] - 0.027(\pm 0.008) [\text{SMR_VSA1}] \\
 & + 0.086(\pm 0.038) [\text{PEOE_VSA-3}] \\
 & + 11.174(\pm 4.976) [\text{GCUT_PEOE_1}] \\
 & - 1.616(\pm 0.792) [\text{PEOE_VSA_FPOS}]
 \end{aligned}$$

$$N = 31, r = 0.918, R^2 = 0.842, S = 0.333, F_{6, 24} = 21.302, F_{5\%, 6, 24} = 2.508, q^2 = 0.789.$$

Leave-one-out cross-validation (LOO-CV) was employed to determine the cross-validated coefficient (q^2) as an internal validation of the models. The best model was then applied to predict the pK_i hH₄R of the test set as an external validation. The R^2 , R_0^2 , and k values were determined accordingly.²²

The correlation between observed, calculated and predicted (leave-one-out) affinity values of the training set is shown in Figure 2. The leave-one-out method resulted in a cross-

validated q^2 of 0.789, which is considered to be good according to the standard set by Erikssons *et al.*²³ As the external validation we initially used Equation 1 to predict the test set. The values of the descriptors and the cross correlation between them can be found in the supporting information.




Figure 2. Graph between observed and calculated affinity of the training set (A). The straight line presents the graph between observed and calculated affinity of the test set (B). The equation and R^2 value are presented in the top left of figure B. The dotted line represents the regression through the origin (the intercept is 0). The equation and R_0^2 value are presented in the bottom right of figure B.

The model has good predictive ability according to the criteria of Golbraikh and Tropsha:²²

i) The q^2 of the training set is larger than 0.5 ($q^2 = 0.789$); ii) the R^2 of the test set is larger than 0.6 ($R^2 = 0.883$); iii) subtraction of the R^2 of the test set by the R_0^2 , divided by the R^2 of the test set is smaller than 0.1 ($(R^2 - R_0^2)/R^2$ is 0.065); iv) the slope of the regression through the origin (the k value) is between the required value of 0.85 and 1.15 ($k = 1.016$).

The QSAR model (Equation 1) shows a positive correlation with **a_ICM**, **PEOE_VSA-3**, and **GCUT_PEOE_1**, and a negative correlation with **PEOE_VSA+5**, **SMR_VSA1**, and **PEOE_VSA_FPOS**. It means that new ligands with high **a_ICM**, **PEOE_VSA-3**, and **GCUT_PEOE_1** and low **PEOE_VSA+5**, **SMR_VSA1**, and **PEOE_VSA_FPOS** value should have higher affinity for the hH₄R.^{18, 24-26}

The results describe the importance of various physicochemical descriptors on the H₄R binding. The main point of diversity in this series of compounds is at the quinazoline 4-position. Substituents at this position were postulated to interact at a particular H₄R binding pocket that was identified by pharmacophore modeling studies.¹⁴ In addition, the QSAR equation could accurately predict the affinity of several new quinazoline

sulfonamides that were synthesized for the SAR study described in this work (Figure 3). The QSAR study will be used in our ongoing efforts to more accurately describe ligand-receptor interaction .





Figure 3. The pK_i of the newly synthesized sulfonamides calculated with equation 1. The level of confidence for the prediction interval is 95% and is determined as calculated $pK_i \pm 2SD$. The observed pK_i values have been taken from table 1. Observed pK_i s marked with an asterisk (*) do not fall within the prediction interval (unpaired t-test).

During the optimization of the quinazoline 4-position for H_4R affinity very little attention was paid to substitution of the all-carbon aromatic ring of the quinazoline heterocycle (positions 5-8 of the quinazoline heterocycle, Table 5).¹³ Substitution at this position has been explored thoroughly in other classes of H_4R compounds, e.g., series of thienopyrrole, quinoxaline, indole and benzimidazole based ligands.^{10,12,27,28} In the case of the new quinazoline scaffold, we explored the introduction of various halogen atoms on the aromatic ring. The observed pK_i 's of the compounds in Table 5 show that a chlorine on the 6-position (compound **54**) is, as expected when considering previously published SAR data, crucial for high H_4R affinity . The SAR described by the compounds in Table 5 is similar to the aforementioned classes of H_4R compounds. Interestingly, an iodine atom on the 6-position gives a comparable affinity to that of the chlorine substituted analogue (compare **54** and **98**). A chlorine atom on the 7-position does not enhance H_4R binding and the lowest potencies are therefore found with compounds **99** and **100** that both lack a halogen atom at the 6-position but occupy the 7-position with a chlorine atom. When the 6-position is occupied with a chlorine or bromine atom and the 7-position is simultaneously

substituted with a chlorine atom, the affinity is restored and quite good affinities are found for compounds **101** ($pK_i = 7.72 \pm 0.16$) and **102** ($pK_i = 7.81 \pm 0.02$). The 6,8-dichloro substitution pattern (compound **103**) and the introduction of a 5-CF₃ group (compound **104**) also give ligands with affinities comparable to that of **54**. This SAR study shows that in the phenyl sulfonamide series a 6-chlorine atom remains the optimal substituent for high H₄R affinity, although several other substitution patterns such as 5-CF₃, 6,8-Cl and 6-I are also well tolerated and give compounds with excellent H₄R affinity.

Table 5: Phenyl sulfonamide substituted quinazolines with various small lipophilic substituents.



No	R ₁	pK_i^a
54	6-Cl	8.31 ± 0.10
98	6-I	8.24 ± 0.06
99	5,7-Cl	6.82 ± 0.03
100	7,8-Cl	6.51 ± 0.04
101	6,7-Cl	7.72 ± 0.16
102	6-Br, 7-Cl	7.81 ± 0.02
103	6,8-Cl	7.95 ± 0.12
104	5-CF ₃	8.09 ± 0.07

^a Measured by displacement of [³H]histamine binding using membranes of HEK cells transiently expressing the human H₄R. pK_i 's are calculated from at least three independent measurements as the mean ± SD.

The most potent examples from this quinazoline sulfonamide series are compounds **54** and **58** that both have higher affinity for the H₄R than histamine ($pK_i = 7.92 \pm 0.07$) and thioperamide ($pK_i = 7.20 \pm 0.06$) (Figure 4A). Both compounds were also evaluated in an H₄R driven CRE-β-galactosidase reporter gene assay (Figure 4B). In this assay, histamine shows full agonistic behavior ($\alpha = 1$) while thioperamide shows inverse agonistic behavior ($\alpha = -1$). Both **54** and **58** were found to act as inverse agonists with respective pIC_{50} values of 7.48 ± 0.14 and 8.00 ± 0.15 . The inverse agonism displayed by **54** ($\alpha = -0.28$) was less pronounced than thioperamide whereas the inverse agonism of **58** ($\alpha = -1.64$) was much more pronounced than thioperamide. *In vivo* inflammatory properties of compound **54** were investigated using a carrageenan-induced paw edema model in rats.²⁹ It has been shown previously that in this model, compounds with affinity for the H₄R can inhibit the swelling of the paw after chemically induced inflammation. The affinity for the rat H₄R of **54**

and **58** was found to be 8.81 ± 0.02 ($n=2$) and 7.00 ± 0.10 ($n=2$) respectively with observed antagonistic behavior for **54** and inverse agonistic behavior for compound **58**. In this *in vivo* model, subcutaneous administration at 10 mg/kg of sulfonamide **54** revealed considerable anti-inflammatory activity (Figure 5). The observed reduction of edema was significant after both 2 and 4 hours. These encouraging results show that the novel sulfonamide compounds described in this publication are interesting candidates for further *in vivo* characterization.




Figure 4. Compounds **54** and **58** bind to the hH_4R with high affinity as determined by $[^3\text{H}]$ histamine displacement. (A) Quinazolines **54** ($\alpha=-1.64$) and **58** ($\alpha=-0.28$) show inverse agonistic behavior in a functional assay performed in parallel with H_4R agonist histamine and H_4R inverse agonist thioperamide (B). The α values for histamine and thioperamide have been arbitrarily set at 1 and -1 respectively. Corresponding pIC_{50} 's values for **54** and **58** are 7.48 ± 0.14 and 8.00 ± 0.15 respectively ($n=3$).




Figure 5. Anti-inflammatory effects of compound **54** on paw edema induced by subplantar injection of carrageenan (1% in CMC) in rats. Data are expressed as mean \pm S.E.M. n=6 rats per group. Comparisons between multiple groups were made by using one-way analysis of variance (ANOVA), followed by Dunnett's test. * P <0.05 and ** P <0.01 compared with vehicle-treated animals (Student t test for grouped data).

Conclusion

During the optimization of the quinazoline heterocycle that was discovered as a good scaffold for high H₄R affinity compounds, two alkyl- and aryl sulfonamide analogues were synthesized from proprietary building blocks. The quinazoline sulfonamides were found to tightly bind to the H₄R and a subsequent SAR study of these compounds indicated that the sulfonamide moiety is crucial for high H₄R affinity. Moreover, the sulfonamide moiety appears to be very tolerant to substitution with a variety of aromatic, aliphatic or fused ring systems. Subsequently, a QSAR model for the affinity of this new series of H₄R ligands was developed with good predictive ability for the affinity of quinazolines with variations in the sulfonamide moiety. In the course of these studies several compounds were discovered with excellent affinity for the H₄R in the low nanomolar range. Additional pharmacological evaluation of two selected analogues revealed that the two analogues that were studied displayed inverse agonism at the human H₄R. When compound **54**, was administered to the rat, it significantly reduced the inflammation caused by the injection of carrageenan in the paw, thereby demonstrating the *in vivo* anti-inflammatory property of this promising class of quinazoline H₄R inverse agonists.

Experimentals

General remarks

Chemicals and reagents were obtained from commercial suppliers and were used without further purification. Yields given are isolated yields unless mentioned otherwise. Flash column chromatography was typically carried out on an Argonaut Flashmaster™ II flash chromatography system, using prepacked Isolute Flash Si II columns with the UV detector operating at 254 nm. All meltingpoints are uncorrected and were measured on an Optimelt Automated Melting Point System from Stanford research systems. ¹H NMR and ¹³C NMR spectra were measured on a Bruker AC200. ¹H NMR spectra of compounds **98-104** were measured on a Bruker Avance 400 at 75°C.

Analytical HPLC-MS analyses were conducted using a Shimadzu LC-8A preparative liquid chromatograph pump system with a Shimadzu SPD-10AV UV-VIS detector with the MS detection performed with a Shimadzu LCMS-2010 liquid chromatograph mass spectrometer. The buffer used for The LCMS analyses is a 0.4% (w/v) NH₄CO₃ solution in water, adjusted to pH 8.0 with NH₄OH. The analyses were performed using the following condition: An Xbridge™ (C18)5μ column (100 mm x 4.6 mm) with the following two solvents; solvent A, 90% MeCN-10% buffer; solvent B, 90% water-10% buffer; flow rate = 2.0 ml/min; Start 95% B, linear gradient to 90% A in 10 min, then 10 min at 90% A, then 10 min at 95% B. Total run time 30 min.

HRMS data was collected using a Bruker micrOTOF-Q (ESI).

In vitro Pharmacology

The pK_i's at the human H₄R were determined according to a procedure described in literature.¹² Functional behavior at the H₄R determined in the CRE-β-galactosidase reporter gene assay was performed as previously reported.¹³

In-vivo pharmacology - Carrageenan-induced edema model

Determination of the anti-inflammatory activity of compound **54** at 30 mg/kg in the carrageenan induced paw edema model for inflammation was performed according to a method described in literature.²⁹

Synthetic methods

General method A: synthesis of phthalimido sulfonamides from their corresponding sulfonyl chloride precursors. The following procedure is representative for the synthesis of intermediates **11** and **12**.

2-phthalimidoethane-*N*-phenylsulfonamide (**9**)

2-Phthalimidoethanesulfonylchloride (2.0 g, 7.3 mmol) was added to a solution of aniline (2.3 g, 24.6 mmol) in chloroform (15 ml) in portions and the resulting mixture was stirred at room temperature for 16 hours. The organic phase was then washed with water and 1 M HCl. Removal of the solvent gave the crude product as a solid that was recrystallized from EtOH to yield 1.76 g (73%) of the title compound as white crystals. ¹H-NMR (CDCl₃) δ (ppm) 7.87-7.83 (m, 2H), 7.77-7.70 (m, 2H), 7.32-7.10 (m, 5H), 4.09-4.03 (m, 2H), 3.47-3.41 (m, 2H).

General method B: deprotection of phtalimido sulfonamides to their corresponding primary amines. The following procedure is representative for the synthesis of intermediates 13a, 13b, 14, 15, 17 and 18.

2-aminoethanesulfonamide hydrochloride (16)

A suspension of 2-phtalimidoethanesulfonamide (1.52 g, 6.78 mmol) was heated at reflux in EtOH (30 ml) after which hydrazine (0.36 ml, 7.41 mmol) (64% in water) was added. After 3 hours a white precipitate formed that was removed by filtration. The filtrate was evaporated to dryness and added to water (150 ml). The aqueous suspension was acidified with conc. HCl and residual insoluble material was filtered off. The clear filtrate was evaporated to dryness and the crude sulfonamide was recrystallized from EtOH/water (9:1) to yield the final product as 764 mg (64%) of white crystals. Mp 134.0-135.0°C. ¹H-NMR (D₂O) δ (ppm) 3.62-3.55 (m, 2H), 3.51-3.44 (m, 2H).

General method C: synthesis of quinazoline-diones from their corresponding anthranilic acid precursors. The following procedure is representative for the synthesis of intermediates 33-36 and 38-39.

6,7-dichloroquinazolin-2,4(1*H*,3*H*)-dione (37)

2-Amino-4,5-dichloro benzoic acid (920 mg, 4.58 mmol) and urea (2.75 g, 45.8 mmol) were stirred at 160°C. After 6 hours the mixture was cooled to 100°C and an equivalent volume of water was added while stirring was continued for 5 minutes. The formed precipitate was filtered off and washed with water to yield a solid cake that was suspended in a solution of 0.5 N NaOH in water. The suspension was heated to boil for 5 minutes and then cooled to r.t. The pH was adjusted to 2 with concentrated HCl and the quinazoline-dione was filtered off. After washing with water:methanol (1:1) the product was dried in vacuo to yield 994 mg (94%) of a light brown powder. ¹H-NMR (DMSO- δ_6) δ (ppm) 7.89 (s,1H), 7.33 (s,1H).

General method D: synthesis of 2,4-dichloroquinazolines from their corresponding quinazoline-dione precursors. The following procedure is representative for the synthesis of intermediates 41-44, 46 and 47.

2,4,6,7-tetrachloroquinazoline (45)

6,7-dichloroquinazolin-2,4(1*H*,3*H*)-dione (800 mg, 3.46 mmol), DIPEA (1.23 ml, 7.27 mmol) and POCl₃ (4.0 ml) were heated at reflux. After 3 hours the reaction mixture was cautiously poured over crushed ice and stirred vigorously. This aqueous mixture was extracted with CH₂Cl₂ DCM and the combined organic layers were washed with brine and dried over Na₂SO₄. Evaporation of the solvent gave a crystalline solid that was redissolved in CH₂Cl₂ after which it was filtered over a pad of silica using CH₂Cl₂ as eluent. Removal of the organic phase gave the product as 657 mg (71%) of a beige solid. ¹H-NMR (CDCl₃) δ (ppm) 8.34 (s,1H), 8.31 (s,1H); ¹³C-NMR (CDCl₃) δ (ppm) 162.67, 156.22, 150.56, 141.75, 134.24, 128.98, 126.55, 121.28.

General method E: synthesis of 2,4-disubstituted quinazolines from their corresponding 2,4-dichloroquinazoline precursors. The following procedure is representative for the synthesis of compounds 3, 49-56, 58-61, 82 and 98-104.

2-(6-chloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-*N,N*-dimethylethanesulfonamide (48)

2,4,6-Trichloroquinazoline (200 mg, 0.86 mmol) was added to a microwave tube containing EtOAc (3.0 ml) and DIPEA (0.32 ml, 1.81 mmol). 2-Aminoethane-*N,N*-

dimethylsulfonamide hydrochloride (162 mg, 0.86 mmol) was then added and the resulting mixture was stirred at r.t. until TLC indicated complete conversion of the starting material to the 4-substituted quinazoline intermediate. *N*-methylpiperazine (1.0 ml) was added and the reaction mixture was heated at 120°C for 10 minutes under microwave irradiation. The obtained suspension was then diluted with EtOAc (~50 ml) and washed with water and brine. Drying of the organic phase with Na₂SO₄ and evaporation of the solvent gave the crude product that was purified over SiO₂ (90 % EtOAc, 5% Et₃N, 5% MeOH) to yield 117 mg (33%, calculated over the two steps) of the title compound as an off-white solid. Mp 172.4-173.6°C; ¹H-NMR (CDCl₃) δ (ppm) 7.45-7.32 (m, 3H), 6.34 (m, 1H), 4.09 (q, *J* = 5.8 Hz, 2H), 3.89 (t, *J* = 5.0 Hz, 4H), 3.25 (t, *J* = 6.0 Hz, 2H), 2.89 (s, 6H), 2.46 (t, *J* = 5.0 Hz, 4H), 2.32 (s, 3H); ¹³C-NMR (CDCl₃) δ (ppm) 158.52, 150.73, 133.19, 127.33, 125.91, 120.15, 110.74, 54.96, 46.43, 46.10, 43.63, 37.28, 35.24; MS (ESI) *m/z* 413 (M+H)⁺.

2-(6-chloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-*N,N*-diethylethanesulfonamide (3)

Prepared according to general method E from 2,4,6-trichloroquinazoline (200 mg, 0.86 mmol) and 2-aminoethane-*N,N*-diethylsulfonamide oxalate (240 mg, 0.88 mmol). Yield: 154 mg (44%). Mp 154.0-156.4°C; ¹H-NMR (CDCl₃) δ (ppm) 7.41-7.27 (m, 3H), 6.32 (m, 1H), 4.01 (q, *J* = 5.8 Hz, 2H), 3.85 (t, *J* = 4.9 Hz, 4H), 3.31-3.17 (m, 6H), 2.41 (t, *J* = 4.9 Hz, 4H), 2.28 (s, 3H), 1.15 (t, *J* = 7.1 Hz, 6H); ¹³C NMR (CDCl₃) δ 158.53, 150.69, 133.10, 127.24, 125.81, 120.23, 110.79, 54.97, 50.61, 46.11, 43.63, 41.41, 35.53, 14.24; MS (ESI) *m/z* 441 (M+H)⁺.

potassium 3-phtalimidopropane-1-sulfonate (5b)

Starting from 3-amino-1-propanesulfonic acid (3.0 g, 9.74 mmol) this compound was prepared according to the procedure described for **5a**.¹⁴ Yield: 6.09 g (100%). ¹H-NMR (D₂O) δ (ppm) 7.74 (s, 4H), 3.71 (t, *J* = 6.9 Hz, 2H), 2.97-2.89 (m, 2H), 2.12-1.98 (m, 2H).

3-phtalimidopropanesulfonylchloride (6b)

Potassium-3-phtalimidopropane-1-sulfonate (6.0 g, 20.9 mmol) was suspended in dry toluene (25 ml) under a nitrogen atmosphere and heated to reflux. Then 4.11 g (19.7 mmol) of PCl₅ was added in portions and the mixture was heated at reflux for 60 minutes. A second portion of 4.11 g (19.7 mmol) of PCl₅ was added and heating was continued for 90 minutes. The reaction mixture was evaporated to dryness and crushed ice was added to the residual solid. When the ice had just molten, the solid was filtered off and dried in vacuo to yield 5.64 g (94%) of a white solid. ¹H-NMR (CDCl₃) δ (ppm) 7.88-7.81 (m, 2H), 7.78-7.71 (m, 2H), 3.87 (t, *J* = 6.5 Hz, 2H), 3.77-3.69 (m, 2H), 2.48-2.34 (m, 2H).

2-phtalimidoethane-*N*-methylsulfonamide (7a)

2-Phtalimidoethanesulfonylchloride (2.0 g, 7.3 mmol) was added portion wise to a solution of 2.0 M methylamine in THF (15 ml) and the solution obtained this way was stirred at room temperature. After 48 hours the reaction mixture was poured in water (50 ml) causing the title compound to precipitate. The product was collected by filtration and recrystallized from EtOH:water, 50:1 to yield: 1.04 g (50%) of the desired product as a white solid. Mp 145.3-147.6 °C (Lit 142-144 °C)³⁰

3-phtalimidopropane-*N*-methylsulfonamide (7b)

Prepared according to general method A from 3-phtalimidopropanesulfonylchloride (2.50 g, 8.69 mmol). Yield: 854 mg (35%). ¹H-NMR (CDCl₃) δ (ppm) 7.82-7.76 (m, 2H), 7.72-

7.64 (m, 2H), 4.13 (br s, 1H), 3.78 (t, $J = 6.8$ Hz, 2H), 3.07-2.99 (m, 2H), 2.74 (d, $J = 5.2$ Hz, 3H), 2.21-1.18 (m, 2H).

2-phtalimidoethane-*N,N*-dimethylsulfonamide (8)

2-Phtalimidoethanesulfonylchloride (2.0 g, 7.31 mmol) was used in a procedure identical to the one used for **7a**. Yield: 1.03 g (50%). $^1\text{H-NMR}$ (CDCl_3) δ (ppm) 7.87-7.79 (m, 2H), 7.75-7.66 (m, 2H), 4.11 (t, $J = 7.1$, 2H), 3.30 (t, $J = 7.1$ Hz, 2H), 2.87 (s, 6H).

2-phtalimidoethane-*N*-(4-iodophenyl)sulfonamide (11)

Prepared according to general method A from 2-phtalimidoethanesulfonylchloride (1.50 g, 5.48 mmol) and 4-iodoaniline (2.70 g, 12.3 mmol). Yield: 1.56 g (62%). $^1\text{H-NMR}$ (CDCl_3) δ (ppm) 10.14 (s, 1H), 7.83 (s, 4H), 7.63 (d, $J = 8.7$ Hz, 2H), 7.00 (d, $J = 8.8$ Hz, 2H), 3.94 (t, $J = 7.1$ Hz, 2H), 3.94-3.44 (m, 2H).

2-(2-(morpholinosulfonyl)ethyl)isoindole-1,3-dione (12)

Prepared according to general method A from 2-phtalimidoethanesulfonylchloride (2.0 g, 7.31 mmol) and morpholine (2.14 ml, 24.6 mmol). Yield: 1.28 g (54%). $^1\text{H-NMR}$ (CDCl_3) δ (ppm) 7.94-7.84 (m, 4H), 3.99 (t, $J = 6.8$ Hz, 2H), 3.62 (t, $J = 4.7$ Hz, 4H), 3.45 (t, $J = 6.8$ Hz, 4H), 3.15 (t, $J = 4.6$ Hz, 4H),.

2-aminoethane-*N*-methylsulfonamide hydrochloride (13a)

Prepared according to general method B from 3-phtalimidoethane-*N*-methylsulfonamide (1.03 g, 3.84 mmol). Yield: 415 mg (72%). $^1\text{H-NMR}$ (D_2O) δ (ppm) 3.53-3.46 (m, 2H), 3.43-3.40 (m, 2H), 2.73 (s, 3H).

3-aminopropane-*N*-methylsulfonamide hydrochloride (13b)

Prepared according to general method B from 3-phtalimidopropane-*N*-methylsulfonamide (847 mg, 3.00 mmol). Yield: 500 mg (88%). $^1\text{H-NMR}$ (D_2O) δ (ppm) 3.31 (t, $J = 7.5$ Hz, 2H), 3.15 (t, $J = 7.7$ Hz, 2H), 2.72 (s, 3H), 2.13 (p, $J = 7.5$ Hz, 2H).

2-aminoethane-*N,N*-dimethylsulfonamide hydrochloride (14)

Prepared according to general method B from 3-phtalimidopropane-*N,N*-dimethylsulfonamide (1.03 g, 3.65 mmol). Yield: 602 mg (87%). $^1\text{H-NMR}$ (D_2O) δ (ppm) 3.49 (s, 4H), 2.89 (s, 6H); $^{13}\text{C NMR}$ (D_2O) δ (ppm) 45.61, 38.31, 35.36.

2-aminoethane-*N*-phenylsulfonamide (15)

Prepared according to general method B from 2-phtalimidoethane-*N*-phenylsulfonamide (1.60 g, 4.84 mmol). The filtrate that was evaporated to dryness was not added to water but was sufficiently pure to be used in the next step without further purification. Yield: 386 mg (40%) of a light yellow solid. $^1\text{H-NMR}$ ($\text{DMSO}-d_6$) δ (ppm) 7.36-7.04 (m, 5H), 3.14 (t, $J = 7.0$ Hz, 2H), 2.88 (t, $J = 6.7$ Hz, 2H).

2-phtalimidoethanesulfonamide (16)

2-Phtalimidoethanesulfonylchloride (2.0 g, 7.3 mmol) was added portion wise to a solution of 0.5 M of ammonia in dioxane (15 ml) and the solution obtained this way was stirred at room temperature. After 48 hours the reaction mixture was poured in water (50 ml) causing the title compound to precipitate. The product was collected by filtration. Yield: 1.52 g (78%) of a white solid. $^1\text{H-NMR}$ ($\text{DMSO}-d_6$) δ (ppm) 7.92-7.13 (m, 4H), 7.06 (s, 2H), 6.88-3.93 (m, 2H), 3.37-3.30 (m, 2H).

2-aminoethane-*N*-(4-iodophenyl)sulfonamide hydrochloride (17) Prepared according to general method B from 2-phtalimidoethane-*N*-(4-iodophenyl)sulfonamide (1.47 g, 3.22 mmol). The title compound was obtained after recrystallisation of the crude hydrochloride salt from water. Yield: 704 mg (60%). ¹H-NMR (DMSO- δ_6) δ (ppm) 8.17 (br m, 3H), 7.70 (d, J = 8.5 Hz, 2H), 7.07 (d, J = 8.6 Hz, 2H), 3.49-3.42 (m, 2H), 3.10 (m, 2H).

2-(morpholinosulfonyl)ethanamine hydrochloride (18)

Prepared according to general method B from 2-(2-(morpholinosulfonyl)ethyl)isoindole-1,3-dione (1.23 g, 3.87 mmol). Yield: 429 mg (57%). ¹H-NMR (D₂O) δ (ppm) 4.90-4.75 (m, 2H), 2.79 (t, J = 4.7 Hz, 4H), 3.59-3.46 (m, 2H), 3.34 (t, J = 4.7 Hz, 4H).

potassium-1-phtalimidpropane-2-carboxylate (20)

To a solution of β -alanine (25.0 g, 0.28 mol) in acetic acid (100 ml) was added potassium acetate (29.5 g, 0.30 mol) and the resulting mixture was heated at reflux for 10 minutes during which a clear solution was obtained. Then phtalic anhydride (44.5 g, 0.30 mol) was added and reflux was continued for 2.5 hours causing a precipitate to form. The mixture was then cooled in an ice bath and the product was filtered off. Washing with acetic acid and a small amount of EtOH abs. furnished the product as 28.0 g (39%) of a white salt. ¹H-NMR (DMSO- δ_6) δ (ppm) 7.88-7.79 (m, 4H), 3.76 (t, J = 7.5 Hz, 2H), 2.53 (t, J = 7.6 Hz, 2H).

3-phtalimido-*N*-methyl-*N*-phenyl-propionamide (22)

To a suspension of **20** (3.0 g, 11.7 mmol) in DCM (15 ml) and DMF (2 drops) was added thionylchloride (0.94 ml, 12.9 mmol) and the resulting mixture was heated at reflux. After 2 hours the solvent was removed and the remaining solid was carefully added to a solution of *N*-methylaniline (3.1 g, 29.3 mmol) in chloroform (15 ml) at 0°C. The reaction was allowed to warm up to room temperature and stirred for 48 hours. After completion the organic phase was washed with 1M HCl and dried over Na₂SO₄. Removal of the solvent yielded a solid that was recrystallized from EtOH abs. to yield 3.38 g (94%) of a white solid. ¹H-NMR (CDCl₃) δ (ppm) 7.79-7.73 (m, 2H), 7.69-7.62 (m, 2H), 7.41-7.14 (m, 5H), 3.92 (t, J = 7.6 Hz, 2H), 3.22 (s, 3H), 2.44 (t, J = 7.5 Hz, 2H).

3-amino-*N*-methyl-*N*-phenyl-propionamide (23)

A suspension of **22** (3.0 g, 9.73 mmol) was heated at reflux in EtOH (50 ml) after which hydrazine (0.34 ml, 10.7 mmol) (64% in water) was added. After 3 hours a white precipitate formed that was removed by filtration. The filtrate was evaporated to dryness to yield g (100%) of the title compound that was used in the next step without further purification. ¹H-NMR (CDCl₃) δ (ppm) 7.41-7.30 (m, 3H), 7.15 (d, J = 6.8 Hz, 2H), 3.23 (s, 3H), 2.88 (t, J = 6.1 Hz, 2H), 2.18 (t, J = 6.1 Hz, 2H).

5,7-dichloroquinazolin-2,4(1*H*,3*H*)-dione (38)

Prepared according to general method C from 6-amino-2,4-dichlorobenzoic acid (2.0 g, 9.71 mmol) and urea (5.83 g, 97.1 mmol). Yield 1.72 g (77%) of a grey solid. ¹H-NMR (DMSO- δ_6) δ (ppm) 11.39 (br s, 2H), 7.32 (d, J = 2.0 Hz, 1H), 7.15 (d, J = 2.0 Hz, 1H).

7,8-dichloroquinazolin-2,4(1*H*,3*H*)-dione (39)

Prepared according to general method C from 2-amino-3,4-dichlorobenzoic acid (2.23 g, 10.81 mmol) and urea (6.49 g, 108.1 mmol). Yield 2.18 g (87%) of a light yellow solid. ¹H-NMR (DMSO- δ_6) δ (ppm) 11.64 (br s, 1H), 10.87 (br s, 1H), 7.86 (d, J = 8.5 Hz, 1H), 7.43 (d, J = 8.5 Hz, 1H).

2,4-dichloro-6-iodoquinazoline (41)

Prepared according to general method D from 6-iodoquinazolin-2,4(1*H*,3*H*)-dione (2.0 g, 6.15 mmol). Yield: 1.73 g (87%); ¹H-NMR (CDCl₃) δ (ppm) 8.59 (d, *J* = 1.9 Hz, 1H), 8.19 (dd, *J* = 1.9 Hz, *J* = 8.9 Hz, 1H), 7.69 (d, *J* = 8.9 Hz, 1H); ¹³C-NMR (CDCl₃) δ (ppm) 162.25, 155.27, 151.16, 144.80, 134.53, 129.18, 123.46, 94.52.

2,4-dichloro-5-trifluoromethylquinazoline (42)

Prepared according to general method D from 5-trifluoromethylquinazolin-2,4(1*H*,3*H*)-dione (814 mg, 3.54 mmol). Yield: 756 mg (80%). ¹H-NMR (CDCl₃) δ (ppm) 8.23-8.17 (m, 2H), 8.00 (t, *J* = 7.9 Hz, 1H).

2,4,7-trichloro-6-bromoquinazoline (43)

Prepared according to general method D from 6-bromo-7-chloroquinazolin-2,4(1*H*,3*H*)-dione (950 mg, 3.45 mmol). Yield: 431 mg (40%). ¹H-NMR (CDCl₃) δ (ppm) 8.52 (s, 1H), 8.10 (s, 1H); ¹³C-NMR (CDCl₃) δ (ppm) 162.50, 156.26, 151.00, 143.34, 130.23, 128.57, 124.18, 121.45.

2,4,6,8-tetrachloroquinazoline (44)

Prepared according to general method D from 6,8-dichloroquinazolin-2,4(1*H*,3*H*)-dione (1.544 g, 6.68 mmol). Yield: 992 mg (55%). ¹H-NMR (CDCl₃) δ (ppm) 8.15 (d, *J* = 2.2 Hz, 1H), 8.02 (d, *J* = 2.2 Hz, 1H); ¹³C-NMR (CDCl₃) δ (ppm) 160.31, 144.80, 143.20, 134.25, 131.16, 130.88, 124.24, 123.34.

2,4,5,7-tetrachloroquinazoline (46)

Prepared according to general method D from 5,7-dichloroquinazolin-2,4(1*H*,3*H*)-dione (1.0 g, 4.33 mmol). Yield: 1.00 g (87%). ¹H-NMR (CDCl₃) δ (ppm) 87.86 (d, *J* = 2.1 Hz, 1H), 7.70 (d, *J* = 2.1 Hz, 1H); ¹³C-NMR (CDCl₃) δ (ppm) 162.09, 156.06, 154.54, 141.29, 132.48, 132.44, 126.78, 118.71.

2,4,7,8-tetrachloroquinazoline (47)

Prepared according to general method D from 7,8-dichloroquinazolin-2,4(1*H*,3*H*)-dione (1.0 g, 4.33 mmol). Yield: 1.03 g (87%). ¹H-NMR (CDCl₃) δ (ppm) 8.11 (d, *J* = 9.0 Hz, 1H), 7.75 (d, *J* = 9.0 Hz, 1H); ¹³C-NMR (CDCl₃) δ (ppm) 164.16, 156.83, 149.78, 141.15, 130.94, 130.44, 124.53, 121.61.

2-(6-chloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-*N,N*-dimethylethanesulfonamide (48)

Prepared according to general method E from 2,4,6-trichloroquinazoline (200 mg, 0.86 mmol) and 2-aminoethane-*N,N*-dimethylsulfonamide hydrochloride (162 mg, 0.86 mmol). Yield: 117 mg (33%). Mp 172.4-173.6°C; ¹H-NMR (CDCl₃) δ (ppm) 7.45-7.32 (m, 3H), 6.34 (m, 1H), 4.09 (q, *J* = 5.8 Hz, 2H), 3.89 (t, *J* = 5.0 Hz, 4H), 3.25 (t, *J* = 6.0 Hz, 2H), 2.89 (s, 6H), 2.46 (t, *J* = 5.0 Hz, 4H), 2.32 (s, 3H); ¹³C-NMR (CDCl₃) δ (ppm) 158.52, 150.73, 133.19, 127.33, 125.91, 120.15, 110.74, 54.96, 46.43, 46.10, 43.63, 37.28, 35.24; MS (ESI) *m/z* 413 (M+H)⁺.

2-(6-chloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-*N*-methylethanesulfonamide (49)

Prepared according to general method E from 2,4,6-trichloroquinazoline (200 mg, 0.86 mmol) and 2-aminoethane-*N*-methylsulfonamide hydrochloride (131 mg, 0.86 mmol). Yield: 117 mg (34%). Mp 187.0-189.2°C; ¹H-NMR (MeOD) δ (ppm) 7.85 (d, *J* = 2.3 Hz, 1H),

7.49 (dd, $J = 2.3$ Hz, $J = 9.0$ Hz, 1H), 7.35 (d, $J = 9.0$ Hz, 1H), 3.99-3.89 (m, 6H), 3.46-3.31 (m, 2H), 2.71 (s, 3H), 2.52 (t, $J = 5.0$ Hz, 4H), 2.34 (s, 3H); $^{13}\text{C-NMR}$ (MeOD) δ (ppm) 160.73, 160.28, 151.72, 134.17, 127.66, 127.28, 122.69, 112.71, 55.96, 46.20, 44.69, 36.96, 29.18; MS (ESI) m/z 399 (M+H) $^+$.

6-chloro-2-(4-methylpiperazin-1-yl)-*N*-(1-(pyrrolidine-1-ylsulfonyl)ethyl)quinazolin-4-amine (50)

Prepared according to general method E from 2,4,6-trichloroquinazoline (100 mg, 0.43 mmol) and 2-(pyrrolidin-1-ylsulfonyl)ethanamine (83 mg, 0.47 mmol). Yield 154 mg (82%). Mp 183.3-185.3°C; $^1\text{H-NMR}$ (CDCl_3) δ (ppm) 7.45 (s, 1H), 7.41-7.32 (m, 2H), 6.33 (br s, 1H), 4.08 (q, $J = 5.8$ Hz, 2H), 3.89 (t, $J = 5.0$ Hz, 4H), 3.39-3.27 (m, 6H), 2.47 (t, $J = 5.0$ Hz, 4H), 2.33 (s, 3H), 1.95-1.88 (m, 4H); $^{13}\text{C-NMR}$ (CDCl_3) δ (ppm) 158.56, 158.52, 150.69, 133.15, 127.29, 125.89, 120.20, 110.79, 54.97, 47.64, 46.10, 43.63, 35.41, 30.80, 25.71; MS (ESI) m/z 439 (M+H) $^+$.

6-chloro-2-(4-methylpiperazin-1-yl)-*N*-(2-(2-methylpiperidin-1-ylsulfonyl)ethyl)quinazolin-4-amine (51)

Prepared according to general method E from 2,4,6-trichloroquinazoline (100 mg, 0.43 mmol) and 2-(2-methylpiperidin-1-ylsulfonyl)ethanamine oxalate (127 mg, 0.43 mmol). Yield 171 mg (85%) of a glassy white solid. $^1\text{H-NMR}$ (CDCl_3) δ (ppm) 7.45-7.33 (m, 3H), 6.35 (br s, 1H), 4.18 (m, 1H), 4.05 (q, $J = 5.8$ Hz, 2H), 3.89 (t, $J = 5.0$ Hz, 4H), 3.63-3.57 (m, 1H), 3.28-3.27 (m, 2H), 3.25-3.00 (m, 1H), 2.46 (t, $J = 5.0$ Hz, 4H), 2.33 (s, 3H), 1.95-1.52 (m, 6H), 1.26 (d, $J = 6.9$ Hz, 3H); $^{13}\text{C-NMR}$ (CDCl_3) δ (ppm) 158.55, 150.70, 133.14, 127.27, 125.87, 120.24, 110.82, 54.98, 51.21, 48.53, 46.11, 43.64, 40.23, 35.64, 30.68, 25.72, 18.01, 16.26; MS (ESI) m/z 467 (M+H) $^+$.

6-chloro-2-(4-methylpiperazin-1-yl)-*N*-(2-(morpholino4-ylsulfonyl)ethyl)quinazolin-4-amine (52)

Prepared according to general method E from 2,4,6-trichloroquinazoline (200 mg, 0.86 mmol) and 4-(2-aminoethylsulfonyl)-morpholine hydrochloride (218 mg, 0.95 mmol). Yield 303 mg (77%). Mp 172.3-174.3°C; $^1\text{H-NMR}$ (CDCl_3) δ (ppm) 7.46 (s, 1H), 7.41-7.34 (m, 2H), 6.27 (m, 1H), 4.15-4.06 (m, 2H), 3.93 (t, $J = 4.4$ Hz, 4H), 3.74 (t, $J = 4.7$ Hz, 4H), 3.28-3.23 (m, 6H), 2.52 (t, $J = 5.0$ Hz, 4H), 2.36 (s, 3H); $^{13}\text{C-NMR}$ (CDCl_3) δ (ppm) 158.52, 158.31, 150.58, 133.27, 127.33, 126.05, 120.16, 110.72, 66.27, 54.84, 47.02, 45.91, 45.57, 43.46, 35.13; MS (ESI) m/z 455 (M+H) $^+$.

2-(6-chloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-*N*-methyl-*N*-phenylethanesulfonamide (53)

Prepared according to general method E from 2,4,6-trichloroquinazoline (200 mg, 0.86 mmol) and 2-aminoethane-*N*-methyl-*N*-phenylsulfonamide. Yield: 231 mg (57%). Mp 150.0-153.3°C; $^1\text{H-NMR}$ (CDCl_3) δ (ppm) 7.43-7.23 (m, 8H), 6.12 (m, 1H), 4.03 (q, $J = 6.0$ Hz, 2H), 3.85 (t, $J = 5.0$ Hz, 4H), 3.39-3.22 (m, 7H), 2.45 (t, $J = 5.0$ Hz, 4H), 2.32 (s, 3H); $^{13}\text{C-NMR}$ (CDCl_3) δ (ppm) 158.45, 150.72, 140.67, 133.16, 129.29, 127.47, 127.29, 126.16, 125.81, 120.18, 110.68, 54.96, 47.74, 46.13, 43.63, 38.24, 35.39; MS (ESI) m/z 475 (M+H) $^+$.

2-(6-chloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-*N*-phenylethanesulfonamide (54)

Prepared according to general method E from 2,4,6-trichloroquinazoline (200 mg, 0.86 mmol) and 2-aminoethane-*N*-phenylsulfonamide (172 mg, 0.86 mmol). Yield: 312 mg (79%). Mp 165.7-166.7°C. $^1\text{H-NMR}$ (CDCl_3) δ (ppm) 7.41-7.07 (m, 8H), 6.20 (m, 1H), 4.00

(m, 2H), 3.80 (m, 4H), 3.52 (t, $J = 5.7$ Hz, 2H), 2.41 (t, $J = 5.0$ Hz, 4H), 2.30 (s, 3H); ^{13}C -NMR (CDCl_3) δ (ppm) 158.57, 158.29, 150.63, 136.07, 133.20, 129.59, 127.26, 125.83, 125.32, 120.25, 110.62, 54.87, 49.89, 46.04, 43.56, 35.89; MS (ESI) m/z 385 (M+H) $^+$.

2-(6-chloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-*N*-(4-iodophenyl)ethanesulfonamide (55)

Prepared according to general method E from 2,4,6-trichloroquinazoline (200 mg, 0.86 mmol) and 2-aminoethane-*N*-(4-iodophenyl)sulfonamide (343 mg, 0.95 mmol). Mp 202.4-206.0°C; Yield: 441 mg (87%). ^1H -NMR (CDCl_3) δ (ppm) 9.69 (br s, 1H), 8.01-7.98 (m, 1H), 7.95 (d, $J = 2.4$ Hz, 1H), 7.61-7.57 (m, 2H), 7.48 (dd, $J = 2.4$ Hz, $J = 8.8$ Hz, 1H), 7.27 (d, $J = 8.8$ Hz, 1H), 7.04-7.01 (m, 2H), 3.85-3.80 (m, 2H), 3.69 (t, $J = 5.0$ Hz, 4H), 3.53-3.50 (m, 2H), 2.31 (t, $J = 5.0$ Hz, 4H), 2.24 (s, 3H); ^{13}C -NMR ($\text{DMSO}-d_6$) δ (ppm) 158.62, 158.01, 150.14, 137.77, 137.68, 132.51, 126.79, 123.94, 121.78, 120.89, 110.87, 87.49, 54.10, 48.71, 45.35, 42.77, 35.22; MS (ESI) m/z 587 (M+H) $^+$.

3-(6-chloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-*N*-methylpropanesulfonamide (56)

2,4,6-Trichloroquinazoline (200 mg, 0.86 mmol) was added to a solution of DIPEA (0.46 ml) and 3-aminopropane-*N*-methylsulfonamide hydrochloride (162 mg) in THF (3.0 ml) and the mixture was stirred overnight at room temperature. The solution was diluted with EtOAc and washed with water and brine. Drying over Na_2SO_4 and removal of the solvent gave a solid that was purified over SiO_2 (EtOAc: Hex, 1:1) to yield the 3-(2,6-dichloroquinazoline-4-amino)-*N*-methylpropanesulfonamide intermediate. This intermediate was added to a microwave tube containing *N*-methylpiperazine (1.0 ml) and THF (3.0 ml) and this solution was heated at 130°C. After 15 minutes the obtained mixture was diluted with water and extracted with EtOAc. The combined organic extracts were dried over Na_2SO_4 and evaporated to give the crude product as a yellow solid. Purification over SiO_2 (EtOAc:MeOH:Et $_3\text{N}$, 90:5:5) gave the title compound as a white solid. Yield: 104 mg (30%). Mp 213.6-214.5°C; ^1H -NMR (CDCl_3) δ (ppm) 7.48-7.32 (m, 3H), 5.91 (m, 1H), 5.91 (m, 1H), 3.88 (t, $J = 5.0$ Hz, 4H), 3.78 (q, $J = 6.2$ Hz, 2H), 3.12 (t, $J = 7.2$ Hz, 2H), 2.78 (s, 3H), 2.45 (t, $J = 5.1$ Hz, 4H), 2.32 (s, 3H), 2.22 (p, $J = 7.1$ Hz, 2H). ^{13}C -NMR (CDCl_3) δ (ppm): 158.88, 158.39, 150.28, 132.30, 126.76, 123.78, 121.81, 111.00, 54.39, 47.14, 45.64, 43.08, 28.34, 22.61; MS (ESI) m/z 413 (M+H) $^+$.

2-(6-chloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-*S*-methylethanesulfone (57)

Prepared according to general method E from 2,4,6-trichloroquinazoline (200 mg, 0.86 mmol) and 2-aminoethylmethylsulfone hydrochloride (151 mg, 0.95 mmol). Yield 296 mg (90%). Mp 191.2-192.0°C; ^1H -NMR (CDCl_3) δ (ppm) 7.45 (s, 1H), 7.41-7.32 (m, 2H), 6.25 (m, 1H), 4.13 (q, $J = 5.8$ Hz, 2H), 3.88 (t, $J = 5.0$ Hz, 4H), 3.43 (t, $J = 5.8$ Hz, 2H), 2.96 (s, 3H), 2.46 (t, $J = 5.0$ Hz, 4H), 2.32 (s, 3H); ^{13}C -NMR (CDCl_3) δ (ppm) 158.61, 158.22, 150.30, 132.48, 126.83, 123.91, 121.75, 110.94, 54.38, 51.85, 45.65, 43.10, 34.34; MS (ESI) m/z 384 (M+H) $^+$.

2-(6-chloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-ethanesulfonamide (58)

Prepared according to general method E from 2,4,6-trichloroquinazoline (200 mg, 0.86 mmol) and 2-aminoethanesulfonamide hydrochloride (130 mg, 0.86 mmol). Yield: 125 mg (38%). Mp 244.9-249.7°C; ^1H -NMR ($\text{DMSO}-d_6$) δ (ppm) 8.23 (m, 1H), 8.04 (d, $J = 2.3$ Hz, 1H), 7.51 (dd, $J = 2.3$ Hz, $J = 8.9$ Hz, 1H), 7.27 (d, $J = 8.9$ Hz, 1H), 3.78 (m, 6H), 2.34 (m, 4H), 2.21 (s, 2H); ^{13}C -NMR ($\text{DMSO}-d_6$) δ (ppm) 158.60, 158.27, 150.25, 132.45, 126.80, 123.86, 121.76, 110.95, 54.38, 52.49, 45.64, 43.09, 35.67; MS (ESI) m/z 461 (M+H) $^+$.

3-(6-chloro-2-(4-methylpiperazin-1-yl)quinazolin-4-ylamino)-*N*-methyl-*N*-phenylpropanamide (59)

Prepared according to general method E from 2,4,6-trichloroquinazoline (200 mg, 0.86 mmol) and 3-amino-*N*-methyl-*N*-phenyl-propionamide (154 mg, 0.86 mmol). Yield 154 mg (41%). Mp 134.4-137.7°C; ¹H-NMR (CDCl₃) δ (ppm) 7.51 (d, *J* = 2.0 Hz, 1H), 7.43-7.30 (m, 5H), 7.09-7.04 (m, 2H), 6.65 (br s, 1H), 3.79-3.77 (m, 6H), 3.26 (s, 3H), 2.46-2.37 (m, 6H), 2.30 (s, 3H); ¹³C-NMR (DMSO-*d*₆) δ (ppm) 169.98, 158.66, 158.23, 150.20, 143.45, 132.22, 129.28, 127.28, 127.00, 126.71, 123.70, 121.79, 111.01, 54.32, 45.66, 42.98, 36.52, 35.23, 32.10; MS (ESI) *m/z* 439 (M+H)⁺.

***N*-(2-(6-chloro-2-(4-methylpiperazin-1-yl)quinazolin-4-ylamino)ethyl)acetamide (60)**

Prepared according to general method E from 2,4,6-trichloroquinazoline (200 mg, 0.86 mmol) and *N*-(2-aminoethyl)-acetamide (88 mg, 0.86 mmol). Yield: 115 mg (37%). Mp 199.1-201.2°C; ¹H-NMR (DMSO-*d*₆) δ (ppm) 8.09-7.99 (m, 3H), 7.49 (dd, *J* = 2.3 Hz, *J* = 8.9 Hz, 1H), 7.26 (d, *J* = 8.9 Hz, 1H), 3.77 (m, 4H), 3.48-3.36 (m, 4H), 2.35 (m, 4H), 2.21 (s, 3H), 1.80 (s, 3H); ¹³C-NMR (DMSO-*d*₆) δ (ppm) 169.25, 158.94, 158.40, 150.25, 132.26, 126.73, 123.72, 123.72, 121.88, 111.07, 54.38, 45.60, 43.03, 37.31, 22.45; MS (ESI) *m/z* 363 (M+H)⁺.

3-[2-[6-Chloro-2-(4-methylpiperazin-1-yl)-quinazolin-4-amino]-ethyl]-thiazolidine-2,4-dione (61)

Prepared according to general method E from 2,4,6-trichloroquinazoline (200 mg, 0.86 mmol) and 3-(2-aminoethyl)-1,3-thiazolidine-2,4-dione (169 mg, 0.86 mmol). Yield: 196 mg (54%). Mp 248.2-249.9°C. ¹H-NMR (DMSO-*d*₆) δ (ppm) 8.20 (m, 1H), 7.97 (d, *J* = 2.3 Hz, 1H), 7.49 (dd, *J* = 2.3 Hz, *J* = 8.9 Hz, 1H), 7.26 (d, *J* = 8.9 Hz, 1H), 4.07 (s, 2H), 3.77-3.36 (m, 8H), 2.35 (m, 4H), 2.20 (s, 3H); ¹³C-NMR (DMSO-*d*₆) δ (ppm) 172.23, 171.86, 159.05, 158.36, 150.30, 132.36, 126.77, 123.78, 121.72, 110.92, 54.46, 45.67, 43.10, 37.18, 33.66; MS (ESI) *m/z* 421 (M+H)⁺.

6-chloro-2-(4-methylpiperazin-1-yl)-*N*-(4-nitrophenethyl)quinazolin-4-amine (82)

Prepared according to general method E from 2,4,6-trichloroquinazoline (200 mg, 0.86 mmol) and 4-nitrophenylethylamine hydrochloride (191 mg, 0.95 mmol). Yield: 212 mg (58%). ¹H-NMR (CDCl₃) δ (ppm) 8.16 (d, *J* = 8.7 Hz, 2H), 7.46-7.33 (m, 5H), 5.49 (br s, 1H), 3.94-3.81 (m, 6H), 3.12 (t, *J* = 7.0 Hz, 2H), 2.48 (t, *J* = 4.8 Hz, 4H), 2.34 (s, 3H); ¹³C-NMR (CDCl₃) δ (ppm) 158.68, 150.80, 146.81, 146.67, 133.04, 129.49, 127.51, 125.67, 123.77, 119.77, 110.64, 55.00, 46.15, 43.68, 41.90, 35.07, 30.80; MS (ESI) *m/z* 427 (M+H)⁺.

2-(6-iodo-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-*N*-phenylethanesulfonamide (98)

Prepared according to general method E from 2,4-dichloro-6-iodoquinazoline (200 mg, 0.62 mmol) and 2-aminoethane-*N*-phenylsulfonamide (134 mg, 0.67 mmol). Yield: 261 mg (76%). Mp 218.7-222.7°C; ¹H-NMR (DMSO-*d*₆) δ (ppm) 9.93 (br s, 1 H), 8.26-8.22 (m, 2H), 7.72 (dd, *J* = 1.8 Hz, *J* = 8.8 Hz, 1H), 7.34-7.18 (m, 3H), 7.12-7.03 (m, 2H), 3.77-3.66 (m, 6H), 3.50-3.42 (m, 2H), 2.50-2.27 (m, 4H), 2.20 (s, 3H); MS (ESI) *m/z* 553 (M+H)⁺.

2-(5,7-dichloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-*N*-phenylethanesulfonamide (99)

Prepared according to general method E from 2,4,5,7-tetrachloroquinazoline (200 mg, 0.75 mmol) and 2-aminoethane-*N*-phenylsulfonamide (164 mg, 0.82 mmol). Yield: 296 mg (80%). Mp 171.6-173.5°C; ¹H-NMR (DMSO-*d*₆) δ (ppm) 7.93 (m, 1H), 7.30-7.26 (m, 2H), 7.23-7.21 (m, 3H), 7.11 (d, *J* = 2.1 Hz, 1H), 7.09-7.05 (m, 1H), 3.94 (q, *J* = 6.4 Hz, 2H), 3.72

(t, $J=5.0$ Hz, 4H), 3.50 (t, $J=6.8$ Hz, 2H), 2.31 (t, $J=5.0$ Hz, 4H), 2.22 (s, 3H); $^{13}\text{C-NMR}$ (CDCl_3) δ (ppm) 163.21, 162.74, 160.33, 143.13, 141.35, 135.00, 134.32, 128.78, 128.68, 127.10, 124.41, 111.74, 59.51, 53.95, 50.88, 48.17, 41.19; MS (ESI) m/z 495 ($\text{M}+\text{H}$) $^+$.

2-(7,8-dichloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-*N*-phenylethanesulfonamide (100)

Prepared according to general method E from 2,4,7,8-tetrachloroquinazoline (200 mg, 0.75 mmol) and 2-aminoethane-*N*-phenylsulfonamide (164 mg, 0.82 mmol). Yield: 306 mg (82%). Mp 205.0-206.8°C; $^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ (ppm) 8.15 (m, 1H), 7.82 (d, $J=8.8$ Hz, 1H), 7.30-7.26 (m, 2H), 7.23-7.21 (m, 2H), 7.19 (d, $J=8.8$ Hz, 1H), 7.10-7.06 (m, 1H), 3.87-3.83 (m, 2H), 3.78 (t, $J=5.0$ Hz, 4H), 3.51-3.47 (m, 2H), 2.34 (t, $J=5.0$ Hz, 4H), 2.24 (s, 3H); $^{13}\text{C-NMR}$ (CDCl_3) δ (ppm) 164.69, 163.67, 154.71, 143.09, 140.53, 134.35, 130.98, 128.88, 127.44, 125.76, 124.38, 114.86, 59.51, 53.93, 50.87, 48.21, 40.60; MS (ESI) m/z 495 ($\text{M}+\text{H}$) $^+$.

2-(6,7-dichloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-*N*-phenylethanesulfonamide (101)

Prepared according to general method E from 2,4,6,7-tetrachloroquinazoline (200 mg, 0.75 mmol) and 2-aminoethane-*N*-phenylsulfonamide (164 mg, 0.82 mmol). Yield: 284 mg (75%). Mp 207.1-209.2°C; $^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ (ppm) 8.15-8.13 (m, 2H), 7.42 (s, 1H), 7.30-7.26 (m, 2H), 7.23-7.20 (m, 2H), 7.09-7.06 (m, 1H), 3.86-3.81 (m, 2H), 3.71 (t, $J=5.0$ Hz, 4H), 3.50-3.47 (m, 2H), 2.31 (t, $J=5.0$ Hz, 4H), 2.22 (s, 3H); $^{13}\text{C-NMR}$ (CDCl_3) δ (ppm) 158.44, 158.34, 151.12, 137.80, 134.90, 129.06, 125.57, 124.25, 123.60, 121.59, 119.08, 109.83, 54.23, 48.57, 45.58, 42.94, 35.23; MS (ESI) m/z 495 ($\text{M}+\text{H}$) $^+$.

2-(6-bromo-7-chloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-*N*-phenylethanesulfonamide (102)

Prepared according to general method E from 6-bromo-2,4,7-trichloroquinazoline (200 mg, 0.64 mmol) and 2-aminoethane-*N*-phenylsulfonamide (140 mg, 0.70 mmol). Yield: 208 mg (60%). Mp 200.4-202.0°C; $^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ (ppm) 9.68 (br s, 1H), 8.29 (s, 1H), 8.15 (m, 1H), 7.42 (s, 1H), 7.30-7.26 (m, 2H), 7.21 (d, $J=7.2$ Hz, 2H), 7.09-7.05 (m, 1H), 3.84-3.80 (m, 2H), 3.71 (t, $J=5.2$ Hz, 4H), 3.48 (t, $J=7.2$ Hz, 2H), 2.30 (t, $J=4.6$ Hz, 4H), 2.22 (s, 3H); MS (ESI) m/z 451 ($\text{M}+\text{H}$) $^+$.

2-(6,7-dichloro-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-*N*-phenylethanesulfonamide (103)

Prepared according to general method E from 2,4,6,8-tetrachloroquinazoline (200 mg, 0.75 mmol) and 2-aminoethane-*N*-phenylsulfonamide (164 mg, 0.82 mmol). Yield: 305 mg (82%). Mp 196.2-197.5°C; $^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ (ppm) 8.14 (t, $J=5.2$ Hz, 1H), 7.95 (d, $J=2.4$ Hz, 1H), 7.70 (d, $J=2.4$ Hz, 1H), 7.30-7.26 (m, 2H), 7.23-7.20 (m, 2H), 7.10-7.07 (m, 1H), 3.84-3.82 (m, 2H), 3.76 (t, $J=5.0$ Hz, 4H), 3.51-3.47 (m, 2H), 2.33 (t, $J=5.0$ Hz, 4H), 2.23 (s, 3H); $^{13}\text{C-NMR}$ ($\text{DMSO-}d_6$) δ 158.75, 157.99, 146.96, 137.79, 131.76, 129.07, 122.74, 121.05, 119.10, 111.55, 54.23, 48.56, 45.60, 42.93, 35.39; MS (ESI) m/z 495 ($\text{M}+\text{H}$) $^+$.

2-(5-trifluoromethyl-2-(4-methylpiperazin-1-yl)quinazoline-4-amino)-*N*-phenylethanesulfonamide (104)

Prepared according to general method E from 2,4-dichloro-5-trifluoromethylquinazoline (200 mg, 0.75 mmol) and 2-aminoethane-*N*-phenylsulfonamide (164 mg, 0.82 mmol). Yield: 308 mg (93%). $^1\text{H-NMR}$ ($\text{DMSO-}d_6$) δ (ppm) 9.74 (br s, 1H), 7.64-7.57 (m, 2H), 7.50

(d, $J=6.0$ Hz, 1H), 7.32-7.28 (m, 2H), 7.24-7.21 (m, 2H), 7.11-7.06 (m, 1H), 6.56-6.55 (m, 1H), 3.98 (q, $J=5.9$ Hz, 2H), 3.74 (t, $J=5.2$ Hz, 4H), 3.47 (t, $J=6.6$ Hz, 2H), 2.32 (t, $J=5.0$ Hz, 4H), 2.23 (s, 3H); MS (ESI) m/z 495 ($M+H$)⁺.

Table 6: Purity and retention times of the synthesised compounds determined by analytical HPLC-MS.^a

No	Compound	Retention time (min)	Purity ^b	No.	Compound	Retention time (min)	Purity ^b
3	VUF10514	12.78	99%	59	VUF10518	12.32	99%
48	VUF10571	11.93	95%	60	VUF10557	10.75	93%
49	VUF10570	11.38	98%	61	VUF10554	11.87	97%
50	VUF10788	12.91	98%	82	VUF10506	14.58	98%
51	VUF10787	14.00	98%	98	VUF10659	13.67	98%
52	VUF10657	12.26	98%	99	VUF10782	14.77	99%
53	VUF10512	13.14	98%	100	VUF10781	14.37	99%
54	VUF10519	10.93	98%	101	VUF10660	14.21	99%
55	VUF10656	13.82	97%	102	VUF10776	14.34	99%
56	VUF10517	11.45	99%	103	VUF10658	14.62	99%
57	VUF10646	11.66	99%	104	VUF10775	13.81	96%
58	VUF10558	12.54	99%				

^a The conditions can be found at the beginning of the experimental section; ^b The purities were calculated as the percentage peak area of the analyzed compound by UV detection.

Table 7: HRMS data for compounds **3**, **48-61**, **82** and **98-104**.^a

No	Compound	MF	MW Calc.	MW Found
3	VUF10514	C19H30ClN6O2S	441.1934	441.1840
48	VUF10571	C17H25ClN6O2S	413.1521	413.1507
49	VUF10570	C16H24ClN6O2S	399.1364	399.1370
50	VUF10788	C19H28ClN6O2S	439.1677	439.1678
51	VUF10787	C21H32ClN6O2S	467.1990	467.1986
52	VUF10657	C19H28ClN6O3S	455.1627	455.1633
53	VUF10512	-	N.D.	N.D.
54	VUF10519	C21H26ClN6O2S	461.1521	461.1532
55	VUF10656	C21H25ClN6O2S	587.0487	587.0491
56	VUF10517	C17H26ClN6O2S	413.1521	413.1509
57	VUF10646	C16H22ClN5O2S	384.1255	384.1251
58	VUF10558	C15H22ClN6O2S	385.1208	385.1194
59	VUF10518	C23H28ClN6O	439.2008	439.2013
60	VUF10557	-	N.D.	N.D.
61	VUF10554	C18H22ClN6O2S	421.1208	421.1211
82	VUF10506	C21H24ClN6O2	427.1644	427.1654
98	VUF10659	C21H25IN6O2S	553.0877	553.0865
99	VUF10782	C21H25Cl2N6O2S	495.1131	495.1147
100	VUF10781	C21H25Cl2N6O2S	495.1131	495.1137
101	VUF10660	C21H25Cl2N6O2S	495.1131	495.1134
102	VUF10776	C21H25BrClN6O2S	539.0626	541.0607
103	VUF10658	C21H25Cl2N6O2S	495.1131	495.1140
104	VUF10775	C22H25F3N6O2S	495.1785	495.1766

^a The conditions can be found at the beginning of the experimental section.

Table 8: The value of the most influential descriptors, together with the observed, calculated and predicted affinity values of the training and test set.

No	a_ICM	PEOE_ VSA+5	SMR_ VSA1	PEOE_ VSA-3	GCUT_ PEOE_1	PEOE_VSA_ FPOS	obsd ρK_i^a	calc ρK_i^b	pred ρK_i^c
1	1.394	0.000	33.571	0.000	-0.368	0.952	5.12	5.28	5.36
2	1.471	0.000	44.571	5.683	-0.386	0.956	5.55	5.72	5.76
3	1.426	0.000	33.571	0.000	-0.366	0.880	5.76	5.61	5.54
4	1.368	0.000	33.571	5.683	-0.390	0.705	5.97	5.77	5.71
5	1.353	0.000	33.571	5.683	-0.390	0.718	5.83	5.67	5.60
6	1.490	0.000	33.571	5.683	-0.390	0.636	6.59	6.60	6.61
7	1.551	0.000	33.571	5.683	-0.371	0.835	7.10	6.85	6.83
8	1.524	0.000	33.571	0.000	-0.367	0.869	6.21	6.19	6.19
9	1.551	0.000	33.571	5.683	-0.382	0.835	6.02	6.73	6.79
10	1.385	0.000	33.571	5.683	-0.358	0.875	6.20	5.96	5.87
11	1.607	0.000	33.571	5.683	-0.394	0.853	6.73	6.90	6.93
12	1.634	0.000	48.531	5.683	-0.407	0.902	6.65	6.43	6.34
13	1.607	0.000	33.571	5.683	-0.396	0.860	6.87	6.86	6.86
14	1.634	0.000	33.571	5.683	-0.372	0.853	7.57	7.30	7.25
15	1.696	12.950	69.953	11.365	-0.384	0.800	6.43	6.42	6.41
16	1.607	0.000	33.571	5.683	-0.386	0.721	7.22	7.20	7.20
17	1.634	0.000	33.571	5.683	-0.383	0.708	8.12	7.41	7.35
18	1.634	0.000	33.571	5.683	-0.397	0.708	7.45	7.26	7.24
19	1.682	0.000	50.357	5.683	-0.371	0.795	6.98	7.24	7.29
20	1.682	0.000	50.357	5.683	-0.371	0.835	6.97	7.17	7.21
21	1.590	0.000	33.571	5.683	-0.397	0.641	6.25	7.11	7.25
22	1.685	6.700	33.571	5.683	-0.404	0.791	7.30	6.98	6.92
23	1.516	0.000	33.571	5.683	-0.389	0.727	6.25	6.62	6.65
24	1.612	0.000	48.531	5.683	-0.397	0.741	6.98	6.67	6.62
25	1.690	0.000	63.491	5.683	-0.399	0.755	6.73	6.68	6.65
26	1.437	0.000	33.571	5.683	-0.361	0.867	6.23	6.24	6.25
27	1.723	0.000	35.090	5.683	-0.361	0.680	8.12	8.19	8.22
28	1.763	0.000	33.571	5.683	-0.394	0.609	8.31	8.21	8.18
29	1.575	0.000	33.571	5.683	-0.392	0.861	6.65	6.72	6.73
30	1.634	12.950	33.571	5.683	-0.395	0.813	6.31	6.41	6.43
31	1.830	27.875	36.695	5.683	-0.394	0.756	6.75	6.77	6.86
32	1.450	0.000	44.571	5.683	-0.389	0.721	5.39	5.94	-
33	1.384	0.000	33.571	0.000	-0.386	0.946	5.07	5.03	-
34	1.500	0.000	33.571	5.683	-0.365	0.852	6.12	6.59	-
35	1.581	0.000	33.571	0.000	-0.372	0.776	6.81	6.62	-
36	1.648	0.000	58.956	5.683	-0.393	0.803	6.36	6.54	-
37	1.686	14.708	33.571	5.683	-0.387	0.822	6.05	6.70	-
38	1.507	0.000	33.571	5.683	-0.395	0.938	6.22	6.16	-
39	1.634	0.000	33.571	5.683	-0.397	0.853	7.05	7.02	-
40	1.607	0.000	33.571	5.683	-0.375	0.759	7.47	7.26	-
41	1.607	0.000	33.571	5.683	-0.358	0.759	7.41	7.45	-
42	1.578	0.000	44.571	5.683	-0.392	0.783	6.44	6.57	-
43	1.527	0.000	64.630	23.425	-0.393	0.738	6.89	7.32	-
44	1.737	0.000	33.571	5.683	-0.393	0.649	8.27	8.01	-

^a ρK_i values taken from table 2in the main article. ^b Calculated from equation 5.^c Determined by leave-one-out method.

Table 8: Correlation matrix for descriptors that influence the affinity of quinazoline derivatives for the human H₄R (pK_i hH₄R).

	pK_i hH ₄ R	a_ICM	PEOE_VSA+5	SMR_VSA1	PEOE_VSA-3	GCUT_PEOE_1	PEOE_VSA_FPOS
pK_i hH ₄ R	1.000						
a_ICM	0.712	1.000					
PEOE_VSA+5	-0.017	0.464	1.000				
SMR_VSA1	-0.020	0.351	0.164	1.000			
PEOE_VSA-3	0.336	0.395	0.266	0.449	1.000		
GCUT_PEOE_1	-0.125	-0.341	-0.215	-0.136	-0.343	1.000	
PEOE_VSA_FPOS	-0.509	-0.302	-0.038	0.095	-0.323	0.326	1.000

Acknowledgements

The authors are grateful for the assistance of Debora Granemann and Mustapha Agalf.

References

1. Oda, T.; Morikawa, N.; Saito, Y.; Masuho, Y.; Matsumoto, S. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. *J. Biol. Chem.* **2000**, *275*:36781-86.
2. Thurmond, R., L., Gelfand, E., W.; Dunford, P., J. The role of histamine H₁ and H₄ receptors in allergic inflammation: the search for new antihistamines. *Nat. Rev. Drug Discov.* **2008**, *7*:41-53.
3. Thurmond, R., L.; Desai, P., J.; Dunford, P., J.; Fung-Leung, W., P.; Hofstra, C., L.; Jiang, W.; Nguyen, S.; Riley, J., P.; Sun, S.; Williams, K., N.; Edwards, J., P.; Karlsson, L. A potent and selective histamine H₄ receptor antagonist with anti-inflammatory properties. *J. Pharmacol. Exp. Ther.* **2004**, *309*:404-13.
4. Zhu, Y.; Michalovich, D.; Wu, H.-L.; Tan, K.B.; Dytko, G.M.; Mannan, I.J.; Boyce, R.; Alston, J.; Tierney, L.A.; Li, X.; Herrity, N.C.; Vawter, L.; Sarau, H.M.; Ames, R. S.; Davenport, C. M.; Hieble, J.P.; Wilson, S.; Bergsma, D.J.; Fitzgerald, L.R. Cloning, expression and pharmacological characterization of a novel human histamine receptor. *Mol. Pharmacol.* **2001**, *59*:434-44.
5. Nakamura, T.; Itadani, H.; Hidaka, Y.; Ohta, M.; Tanaka, K. Molecular cloning and characterization of a new human histamine receptor, HH₄R. *Biochem. Biophys. Res. Commun.* **2000**, *279*:615-20. O'Reilly, M.; Alpert, R.; Jenkinson, S.; Gladue, R., P.; Foo, S.; Trim, S.; Peter, B.; Trevethick, M.; Fidock, M. Identification of a histamine H₄ receptor on human eosinophils--role in eosinophil chemotaxis. *J. Recept. Signal Transduct. Res.* **2002**, *22*:431-48.
6. O'Reilly, M.; Alpert, R.; Jenkinson, S.; Gladue, R., P.; Foo, S.; Trim, S.; Peter, B.; Trevethick, M.; Fidock, M. Identification of a histamine H₄ receptor on human eosinophils--role in eosinophil chemotaxis. *J. Recept. Signal Transduct. Res.* **2002**, *22*:431-48.
7. Gutzmer, R.; Diestel, C.; Mommert, S.; Kother, B.; Stark, H.; Wittmann, M.; Werfel, T. Histamine H₄ receptor stimulation suppresses IL-12p70 production and mediates chemotaxis in human monocyte-derived dendritic cells. *J. Immunol.* **2005**, *174*:5224-32.
8. Takeshita, K.; Sakai, K. I.; Bacon, K., B.; Ganter, F. Critical role of L-selectin and histamine H₄ receptor in zymosan-induced neutrophil recruitment from the bone marrow: comparison with carrageenan. *J. Pharmacol. Exp. Ther.* **2004**, *310*:272-80.
9. Takeshita, K.; Sakai, K. I.; Bacon, K., B.; Ganter, F. Critical role of histamine H₄ receptor in leukotriene B₄ production and mast cell-dependent neutrophil recruitment induced by zymosan in vivo. *J. Pharmacol. Exp. Ther.* **2003**, *307*:1072-78.
10. Venable, J., D.; Cai, H.; Chai, W.; Dvorak, C., A.; Grice, C., A.; Jablonowski, J. A.; Shah, C., R.; Kwok, A., K.; Ly, K., S.; Pio, B.; Wei, J.; Desai, P., J.; Jiang, W.; Nguyen, S.; Ling, P.; Wilson, S., J.; Dunford, P., J.; Thurmond, R., L.; Lovenberg, T., W.; Karlsson, L.; Carruthers, N., I.; Edwards, J., P. Preparation and biological evaluation of indole, benzimidazole, and thienopyrrole piperazine carboxamides: potent human histamine h(4) antagonists. *J. Med. Chem.* **2005**, *48*:8289-98.
11. Lim, H.D.; van Rijn, R. M.; Ling, P.; Bakker, R.A.; Thurmond, R.L.; Leurs, R. Evaluation of histamine H₁-, H₂-, and H₃-receptor ligands at the human histamine H₄ receptor: Identification of 4-methylhistamine as the first potent and selective histamine H₄ receptor agonist. *J. Pharmacol. Exp. Ther.* **2005**, *314*:1310-21.
12. Smits, R., A.; Lim, H., D.; Hanzer, A.; Zuiderveld, O., P.; Guaita, E.; Adami, M.; Coruzzi, G.; Leurs, R.; de Esch I., J., P. Fragment based design of new H₄ receptor-ligands with anti-inflammatory properties in vivo. *J. Med. Chem.* **2008**, *51*:2457-67.
13. Smits, R., A.; de Esch I., J., P.; Zuiderveld, O., P.; Broeker, J.; Sansuk, K.; Guaita, E.; Coruzzi, G.; Adami, M.; Haaksma, E.; Leurs, R. The discovery of quinazolines as histamine H₄ receptor inverse agonists using a scaffold hopping approach. *J. Med. Chem.* Accepted for publication

14. Smits, R.A.; Lim, H.D.; Stegink, B.; Bakker, R.A.; de Esch, I.J.P.; Leurs, R. Characterization of the histamine H₄ receptor binding site: Part I. Synthesis and pharmacological evaluation of dibenzodiazepine derivatives. *J. Med. Chem.* **2005**, 49:4512-6.
15. Winterbottom, R.; Clapp, J., W.; Miller, W., H.; English, J., P.; Roblin, R., O. Studies in chemotherapy. XV. Amides of pantoyltaurine. *J. Am. Chem. Soc.* **1947**, 69:1393-1400.
16. Miller, E.; Sprague, J., M.; Kissinger, L., W.; McBurney, L., F. The preparation of some amino sulfonamides. *J. Am. Chem. Soc.* **1940**, 62:2099-2103.
17. Lee, A., H., F.; Kool, E., T. Novel Benzopyrimidines as Widened Analogues of DNA Bases. *J. Org. Chem.* **2005**, 70:132-140.
18. MOE: *Molecular Operating Environment*, version 2006.08; Chemical Computing Group, Inc.: Montreal, Canada, 2006.
19. Shahapurkar, S.; Pandya, T.; Kawathekar, N.; Chaturvedi, S. C., Quantitative structure activity relationship studies of diaryl furanones as selective COX-2 inhibitors. *Eur. J. Med. Chem.* **2004**, 39:899-904.
20. Halgren, T. A., Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. *J. Comp. Chem.* **1996**, 17:490-519.
21. Halgren, T. A., Merck molecular force field. III. Molecular geometries and vibrational frequencies for MMFF94. *J. Comp. Chem.* **1996**, 17:553-86.
22. Golbraikh, A.; Tropsha, A., Beware of q²! *J. Mol. Graph. Model.* **2002**, 20:269-76.
23. Eriksson, L.; Jaworska, J.; Worth, A. P.; Cronin, M. T.; McDowell, R. M.; Gramatica, P., Methods for reliability and uncertainty assessment and for applicability evaluations of classification- and regression-based QSARs. *Environ. Health Perspect.* **2003**, 111:1361-75.
24. Gasteiger, J.; Marsili, M., Iterative partial equalization of orbital electronegativity - a rapid access to atomic charges. *Tetrahedron* **1980**, 36:3219-28.
25. Petitjean, M., Applications of the radius-diameter diagram to the classification of topological and geometrical shapes of chemical compounds. *J. Chem. Inf. Comp. Sci.* **1992**, 32:331-37.
26. Wildman, S. A.; Crippen, G. M., Prediction of Physicochemical Parameters by Atomic Contributions. *J. Chem. Inf. Comp. Sci.* **1999**, 39:868 -73.
27. Jablonowski, J.A.; Grice, C.A.; Dvorak, C.A.; Venable, J.D.; Kwok, A.K.; Ly, K.S.; Wei, J.; Baker, S.M.; Desai, P.J.; Jiang, W.; Wilson, S.J.; Thurmond, R.L.; Karlsson, L.; Edwards, J.P.; Lovenberg, T.W.; Carruthers, N.I. The first potent and selective non-imidazole human histamine H₄ receptor antagonists. *J. Med. Chem.* **2003** 19:3957-60.
28. Terzioglu, N.; van Rijn, R. M.; Bakker, R. A.; de Esch, I. J. P.; Leurs, R. Synthesis and structure-activity relationships of indole- and benzimidazole piperazines as histamine H₄ receptor antagonists. *Bioorg. and Med. Chem. Lett.* **2004** 14: 5251-56.
29. Coruzzi, G.; Adami, M.; Guaita, E.; de Esch, I., J., P.; Leurs, R. Antiinflammatory and antinociceptive effects of the selective histamine H₄-receptor antagonists JNJ7777120 and VUF6002 in a rat model of carrageenan-induced inflammation. *Eur. J. Pharmacol.* **2007**, 563:240-244.
30. Andersen, L.; Sundman, L.-O.; Linden, I.-B.; Kontro, K.; Oja, S., S. Synthesis and anticonvulsant properties of some 2-aminoethanesulfonic acid (Taurine) derivatives. *J. Pharm. Sci.* **1984** 73:106-8